Verinurad (mg) | Cmax (ng/mL) | AUC0–24 (ng·hour/mL) | Tmax (hour) | t½ (hour)* | fe0–24 (%) |
2.5 | 4.28 (3.33–5.49) | 33.9 (25.4–45.3) | 3.83 (0.967–9.83) | 9.40 (6.97–12.7) | 0.711 (0.462–1.09) |
5 | 8.20 (7.17–9.37) | 68.4 (56.1–83.2) | 3.83 (1.97–8.02) | 13.4 (10.0–17.8) | 0.844 (0.600–1.19) |
7.5 | 11.2 (9.07–13.7) | 92.0 (74.8–113) | 3.00 (1.00–9.97) | 12.0 (8.33–17.4) | 0.679 (0.500–0.920) |
10 | 15.3 (13.1–18.0) | 145 (125–167) | 3.43 (1.50–6.02) | 20.0 (12.2–32.8) | 0.868 (0.669–1.13) |
15 | 22.5 (18.6–27.2) | 194 (158–238) | 3.88 (1.00–6.02) | 12.4 (8.12–19.0) | 0.634 (0.463–0.869) |
20 | 27.6 (23.2–32.7) | 261 (218–313) | 3.97 (1.50–6.02) | 15.8 (11.2–22.3) | 0.824 (0.589–1.15) |
Tmax values are presented as median (range).
*Terminal t½ values were calculated from a period of less than twofold of the calculated t½ value in more than half the subjects in the same dose group.
AUC0–24, area under the plasma concentration–time curve from time zero to 24 hours postdose; Cmax, maximum observed concentration; fe0–24, fraction excreted in urine as unchanged drug or metabolite; Tmax, time of maximum observed plasma concentration.